Business Context and Reporting Period
Company: ICU Medical, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2005
Business Overview: ICU Medical develops, manufactures, and markets disposable medical devices, primarily for intravenous (I.V.) therapy and critical care. The company operates principally in one segment. A significant strategic shift occurred on May 1, 2005, with the acquisition of a manufacturing facility from Hospira, Inc. and the commencement of a 20-year Manufacturing, Commercialization and Development Agreement (MCDA).
Key Financial Metrics
| Metric ($ in thousands) | Three Months Ended June 30, 2005 |
Three Months Ended June 30, 2004 |
Six Months Ended June 30, 2005 |
Six Months Ended June 30, 2004 |
|---|---|---|---|---|
| Total Revenue | $40,693 | $21,664 | $67,778 | $43,898 |
| Gross Profit | $16,333 | $12,064 | $31,558 | $24,484 |
| Gross Margin % (of Net Sales) | 39% | 54% | 45% | 54% |
| Net Income | $4,739 | $3,410 | $9,156 | $7,550 |
| Diluted EPS | $0.31 | $0.23 | $0.61 | $0.50 |
| Cash & Cash Equivalents | $6,876 | — | $6,876 | — |
| Liquid Investments | $57,425 | — | $57,425 | — |
| Total Cash & Investments | $64,301 | — | $64,301 | — |
| Working Capital | $103,195 | — | $103,195 | — |
| Net Cash from Operating Activities | — | — | $7,244 | $16,227 |
Note: Working Capital calculated as Current Assets ($117,165) minus Current Liabilities ($13,970) as of June 30, 2005.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 88% in Q2 2005 and 54% in the first six months of 2005 compared to the prior year periods. This surge is primarily driven by the new MCDA with Hospira, which generated $13.2 million in sales in Q2 2005 alone.
- Gross Margin Compression: Gross margins declined significantly (from 54% to 39% in Q2) due to the inclusion of lower-margin critical care products manufactured for Hospira under the MCDA (approx. 15% margin) and lower-margin Punctur-Guard products. Excluding these new lines, traditional product margins remained in the 51-52% range.
- Balance Sheet Shifts: Accounts receivable increased by $17.9 million (from $8.9M to $26.8M), largely due to new sales to Hospira. Inventory increased by $7.8 million, driven by the acquisition of Hospira's inventory and increased raw materials for the new facility.
- Operating Expenses: Selling, General, and Administrative (SG&A) expenses rose 45% in Q2 and 44% in the six-month period, attributed to patent litigation costs ($1.2M increase in Q2), compensation increases, and costs associated with the new Salt Lake City facility.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- MCDA Performance: Management estimates sales under the MCDA will approximate $40 million in 2005 with small profits, expecting increasing sales and profits in future years as manufacturing efficiencies are realized.
- Margin Expectations: Gross margins on traditional products are expected to be in the 53-55% range for the remainder of 2005. Overall margins are expected to improve as the company implements cost-saving manufacturing processes for the MCDA products.
- Capital Expenditures: Estimated capital expenditures for the remainder of 2005 (excluding Salt Lake City) are approximately $6.6 million, bringing the full-year total to roughly $10.0 million.
- Manufacturing Relocation: The company is moving molding and automated assembly from San Clemente and Connecticut to Salt Lake City, and manual assembly to Mexico. Completion is expected by early 2007.
Risks and Contingencies
- Customer Concentration: Hospira accounted for 75% of total revenues in Q2 2005 and 69% for the six months ended June 30, 2005. The company is highly dependent on Hospira's sales and marketing efforts.
- Integration Risks: Significant risks exist regarding the relocation of manufacturing facilities, retention of key personnel, and the ability to achieve projected cost savings under the MCDA.
- Patent Litigation: Ongoing litigation against Alaris Medical Systems (Cardinal Health) regarding patent infringement. A settlement with B. Braun Medical was reached in April 2005.
- Regulatory and Market Risks: Dependence on FDA approvals, potential price erosion due to competition, and the impact of healthcare cost reduction pressures.
Investor Verification Checklist
- Hospira Dependency: Verify the stability of the relationship with Hospira, which represents nearly 70% of revenue, and the terms of the 20-year MCDA.
- Margin Trajectory: Monitor whether gross margins on MCDA products improve from the current ~15% as manufacturing efficiencies are realized.
- Accounts Receivable: Assess the collectibility of the $26.8 million receivable balance, a significant portion of which is owed by a single customer (Hospira).
- Integration Execution: Track the progress of the manufacturing relocation to Salt Lake City and Mexico to ensure no production interruptions or quality issues.
- Patent Litigation: Follow the outcome of the lawsuit against Alaris Medical Systems, as a loss could impact market share and pricing power for CLAVE products.
- Stock-Based Compensation: Note the upcoming adoption of SFAS 123(R) on January 1, 2006, which will require expensing stock options, potentially impacting future reported earnings.